A Study of S-740792 in Healthy Adult Study Participants

Phase

Condition

N/A

Treatment

S-740792 Tablet

S-740792

S-740792 Suspension

Clinical Study ID

NCT06724978

2318VA711

Ages 18-55
All Genders
Accepts Healthy Volunteers

Study Summary

This is a 3-part study of S-740792 in healthy adult participants. Part 1 (single-ascending-dose and food effect) will investigate the safety, tolerability, and pharmacokinetics (PK) of S-740792. Part 2 (multiple-ascending-dose and drug-drug interaction) will investigate the safety, tolerability, and PK of S-740792, in addition, the effect of multiple doses of S-740792 on the PK of midazolam. Part 3 will investigate the relative bioavailability of S-740792 tablet compared to S-740792 suspension and the food effect on the PK of the S-740792 tablet.

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

Body mass index within the range 18.5 to 30.0 kilograms/meter squared (inclusive).

Exclusion

Key Exclusion Criteria:

History or presence of cardiovascular, respiratory, hepatic, renal,gastrointestinal, endocrinological, hematological, or neurological disorders capableof significantly altering the absorption, metabolism, or elimination of drugs;constituting a risk when taking the study intervention; or interfering with theinterpretation of data.
Participants who require medication or other treatment (for example, dietaryrestrictions or physical therapy).
Participants who have participated in any other clinical study involving aninvestigational study intervention or any other type of medical research within 28days or 5 half-lives of that drug (if known), whichever is longer before signing ofthe informed consent form for this study or who are currently participating in sucha study.
Positive test results of the following at screening or within 6 months prior toadministration of study intervention:
hepatitis B surface antigen
hepatitis C virus antibody
serological test for syphilis
human immunodeficiency virus antigen/antibody
drug screen
alcohol screen
Participants who have used tobacco or nicotine-containing products (includingelectronic-cigarette, pipe tobacco, cigar, chewing tobacco, nicotine patch, andnicotine gum) within 6 months prior to admission or a positive cotinine test atscreening or on admission.

Note: Additional inclusion/exclusion criteria may apply, per protocol.

Study Design